Showing results (141-150 of 166) with videos related to
Sort By:
Pageof 17
Journal of the American College of Cardiology|March 26, 2024
Stratifying Disease Progression in Patients With Cardiac ATTR AmyloidosisAdam Ioannou, Francesco Cappelli, Michele Emdin, et al.JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.European Heart Journal|September 1, 2024
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialCaroline J Coats, Ahmad Masri, Roberto Barriales-Villa, et al.Circulation|November 18, 2024
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialDaniel P Judge, Julian D Gillmore, Kevin M Alexander, et al.Journal of the American College of Cardiology|June 12, 2024
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyAldostefano Porcari, Francesco Cappelli, Christian Nitsche, et al.JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.JAMA Cardiology|January 22, 2025
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid InfiltrationAldostefano Porcari, Yousuf Razvi, Francesco Cappelli, et al.Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.Pageof 17